Some traders like to gamble on big news events that could have a dramatic effect on a particular stock.
For example, the release of a company’s earnings report could cause the underlying stock to jump to new highs, or drop to significant lows. Although most investors may not be interested in such an event, some traders are.
Unfortunately, earnings season comes and goes. However, thanks to the biotechnology industry there are stocks with major news events coming out all of the time.
In addition to the same earnings releases, FDA announcements are commonplace and can cause major pops and drops for the underlying stocks.
Here are a few biotech stocks with possible FDA announcements coming up soon.
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).
Phase 2 open label data of Patisiran for Familial Amyloidotic Polyneuropathy in patients with ATTR due mid-2015.
The stock closed yesterday at $114.21/share
- Esperion Therapeutics, Inc. (NASDAQ: ESPR).
Phase 2 data of ETC-1002-014 for hypercholesterolemia and hypertension due mid-2015.
Esperion closed at $78.28/share yesterday.
- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT).
Completion of NDA filing of Obeticholic acid for primary biliary cirrhosis planned in Q2 of 2015.
Yesterday, the stock closed at $240.39/share
- Sarepta Therapeutics, Inc. (NASDAQ: SPRT).
Rolling NDA filing of Eteplirsen for Duchenne muscular dystrophy to be completed mid-2015.
Sarepta finished the day yesterday at $28.18/share
- Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR).
Phase 1/2 final data of TKM-PLK1 for gastrointestinal neuroendocrine tumors due mid-2015.
Tekmira closed at $11.81/share yesterday.
All data has been obtained from BioPharmCatalyst.
Obviously, investors must conduct their own due diligence before investing in any stock, but whether one is looking to avoid or capitalize on a news event, the biotechs should be names to watch.